ERBB2 and neoplasm: This confirms that the HER2-LsbMDDs non-covalently bound of HER2 targeting BsAbs to the LsbMDDs was able to enhance the targetability to the cells that over-expressed HER2 on its cell membranes, resulting in an increase in cellular uptake, whereas those without the tumor targeting ligands (LsbMDDs) or with a non-expressing targeting ligand of DNS (DNS-LsbMDDs), were unable to enhance the cellular uptake.